Edison Investment Research Comments on CytRx Corporation Following Positive Aldoxorubicin Data

In a report published Thursday, Edison Investment Research analyst Dr. Mike Aitkenhead commented on recent developments related to

. In the report, Edison Investment Research noted, “Following positive aldoxorubicin data in soft tissue sarcoma (STS) and glioblastoma (GBM), CytRx has raised $22.5m to fund ongoing clinical trials in these and other indications. Next key news is final Phase IIb data in front-line STS in Q413. Our revised rNPV is $173.3m ($4.30/share), which could rise to $204.1m if final Phase IIb results are positive.” CytRx Corporation closed on Wednesday at $2.23.